JP2011528654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528654A5
JP2011528654A5 JP2011516733A JP2011516733A JP2011528654A5 JP 2011528654 A5 JP2011528654 A5 JP 2011528654A5 JP 2011516733 A JP2011516733 A JP 2011516733A JP 2011516733 A JP2011516733 A JP 2011516733A JP 2011528654 A5 JP2011528654 A5 JP 2011528654A5
Authority
JP
Japan
Prior art keywords
formula
compound
optionally substituted
compound according
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516733A
Other languages
English (en)
Japanese (ja)
Other versions
JP6084770B2 (ja
JP2011528654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048943 external-priority patent/WO2009158668A1/en
Publication of JP2011528654A publication Critical patent/JP2011528654A/ja
Publication of JP2011528654A5 publication Critical patent/JP2011528654A5/ja
Application granted granted Critical
Publication of JP6084770B2 publication Critical patent/JP6084770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516733A 2008-06-26 2009-06-26 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート Active JP6084770B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13314808P 2008-06-26 2008-06-26
US61/133,148 2008-06-26
US19205008P 2008-09-15 2008-09-15
US61/192,050 2008-09-15
PCT/US2009/048943 WO2009158668A1 (en) 2008-06-26 2009-06-26 Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015126754A Division JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Publications (3)

Publication Number Publication Date
JP2011528654A JP2011528654A (ja) 2011-11-24
JP2011528654A5 true JP2011528654A5 (enExample) 2012-08-16
JP6084770B2 JP6084770B2 (ja) 2017-02-22

Family

ID=41444985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011516733A Active JP6084770B2 (ja) 2008-06-26 2009-06-26 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート
JP2015126754A Pending JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015126754A Pending JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Country Status (7)

Country Link
US (2) US8680315B2 (enExample)
EP (1) EP2306986B1 (enExample)
JP (2) JP6084770B2 (enExample)
CN (1) CN102076331B (enExample)
DK (1) DK2306986T3 (enExample)
ES (1) ES2672526T3 (enExample)
WO (1) WO2009158668A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
US8703907B2 (en) * 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
JP5977229B2 (ja) * 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
CA2837979C (en) 2011-06-06 2021-03-30 Starpharma Pty Ltd Dendrimers comprising terminal pharmaceutically active agents and terminal pharmacokinetic modifying agents
EP2755691B1 (en) * 2011-09-07 2018-08-22 Prolynx LLC Hydrogels with biodegradable crosslinking
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
WO2013059323A1 (en) * 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
WO2013170272A2 (en) * 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
CN106232131A (zh) * 2013-10-22 2016-12-14 普洛林克斯有限责任公司 生长抑素和其类似物的结合物
TWI727919B (zh) 2013-12-19 2021-05-21 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
WO2016046301A1 (en) 2014-09-26 2016-03-31 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
EP3429608A4 (en) 2016-03-16 2019-12-11 Prolynx LLC CONJUGATES WITH EXTENDED RELEASE OF EXENATID ANALOG
CN106177977B (zh) * 2016-07-11 2020-09-04 天津科技大学 一种抗肿瘤药物三元偶联物及合成和应用
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
KR102811484B1 (ko) 2018-07-19 2025-05-22 스타파마 피티와이 리미티드 치료 덴드리머
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
US20220257781A1 (en) * 2018-09-06 2022-08-18 Seikagaku Corporation Polymer conjugate bonded to tertiary amine compound or imine compound and production method therefor
JPWO2020067507A1 (ja) * 2018-09-28 2021-08-30 生化学工業株式会社 第1級アミン化合物又は第2級アミン化合物−酸性多糖コンジュゲートとその製造方法
WO2020206358A1 (en) * 2019-04-05 2020-10-08 Prolynx Llc Improved conjugation linkers
WO2020254197A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
MX2022001528A (es) 2019-08-07 2022-03-11 Prolynx Llc Esterilizacion con vapor de hidrogeles reticulados por enlazadores beta-eliminativos.
CN110423355B (zh) * 2019-08-29 2021-09-14 武汉轻工大学 羧甲基化莲藕多糖-曲古霉素a轭合物的制备方法
JP7784993B2 (ja) 2019-09-30 2025-12-12 奥金生命科学(宜興)有限公司 タンパク質-巨大分子コンジュゲート及びその使用方法
IL297329A (en) 2020-04-22 2022-12-01 Merck Sharp & Dohme Llc Dimeric interleukin-2 beta gamma receptor-biased human interleukin-2 conjugates conjugated to soluble non-peptide polymers.
CN120919341A (zh) * 2021-04-09 2025-11-11 南京大学 缀合物及其制备方法和用途
CN121419789A (zh) * 2023-05-16 2026-01-27 南京大学 缀合物及其制备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501507A (ja) * 1986-05-16 1988-06-09 エカ ノーベル アクチェボラーグ 光学活性試薬および対掌体アミン化合物の測定法
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
CA2262502C (en) * 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
JPH11130711A (ja) * 1997-10-24 1999-05-18 Teijin Ltd 1α,24,25−トリヒドロキシビタミンD3類の合成中間体およびその製造法
AU1345600A (en) * 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6114566A (en) * 1999-05-24 2000-09-05 Board Of Trustees Operating Michigan State University 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof
JP2003528939A (ja) * 1999-09-03 2003-09-30 スクール オブ ファーマシー, ユニヴァーシティ オブ ロンドン 分解性ポリマー
US6861162B2 (en) 2002-08-28 2005-03-01 Cityu Research Ltd. Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
WO2004089279A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
JP4950022B2 (ja) * 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
JP2006067889A (ja) 2004-09-01 2006-03-16 Japan Science & Technology Agency Peoと二本鎖核酸のコンジュゲート
US20080152660A1 (en) 2005-03-03 2008-06-26 Bradshaw Curt W Anti-Angiogenic Compounds
CA2619533C (en) 2005-08-17 2014-02-04 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
JP5224016B2 (ja) * 2006-03-10 2013-07-03 晃二 有光 感活性エネルギー線塩基発生剤、感活性エネルギー線塩基発生剤組成物、塩基反応性組成物及びパターン形成方法
WO2008058016A2 (en) 2006-11-02 2008-05-15 University Of Virginia Patent Foundation Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
DK2279007T3 (en) * 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone

Similar Documents

Publication Publication Date Title
JP2011528654A5 (enExample)
JP5249016B2 (ja) タキサン類の高分子結合体
JP2013525080A5 (enExample)
JP2016528174A5 (enExample)
JP2012526548A5 (enExample)
CN102050953B (zh) 一种可还原降解超分子水凝胶的制备方法
JP2015528002A5 (enExample)
JP6159973B2 (ja) ポリオキサゾリンポリマー及びそれらの製造方法、これらのポリマーのコンジュゲート並びにそれらの医学的使用
JP2014528466A5 (enExample)
JP2010521485A5 (enExample)
JP2011080089A5 (enExample)
JP2013523896A5 (enExample)
JP2016153410A5 (enExample)
JP2012504608A5 (enExample)
JP2017511322A5 (enExample)
JP5548365B2 (ja) 核酸系代謝拮抗剤の高分子誘導体
JP2020514300A5 (enExample)
JP2005504006A5 (enExample)
JP2014521661A5 (enExample)
JP2012502990A5 (enExample)
JP2009521545A5 (enExample)
JP2009535358A5 (enExample)
JP2009504783A5 (enExample)
JP2009502743A5 (enExample)
JP2017523781A5 (enExample)